Superior Vena Cava Syndrome

Overview

Superior vena cava syndrome (SVCS) is a clinical syndrome resulting from obstruction of blood flow through the superior vena cava (SVC), leading to impaired venous drainage from the head, neck, upper extremities, and upper thorax. The condition manifests with characteristic symptoms of facial and upper body swelling, dyspnoea, and dilated collateral veins. [1]

SVCS occurs in approximately 15,000 cases annually in the United States, with malignancy accounting for 60-85% of cases in contemporary series. [2,3] Lung cancer, particularly small cell lung cancer (SCLC), represents the most common malignant cause (50-81% of malignant cases), followed by non-Hodgkin lymphoma (2-21%). [2,4] Benign causes, predominantly catheter-related and device-related thrombosis, now account for 15-40% of cases due to increasing use of central venous catheters, pacemaker leads, and implantable cardioverter-defibrillators. [5,6]

Historically considered an oncological emergency requiring immediate radiation therapy, modern evidence demonstrates that SVCS is rarely life-threatening, and tissue diagnosis prior to treatment improves long-term outcomes in malignant cases. [7,8] The treatment approach differs substantially between malignant and benign aetiologies, emphasising the critical importance of establishing a definitive diagnosis before initiating therapy.

Epidemiology

Incidence and Prevalence

• Annual incidence: Approximately 15,000 cases in the United States [2]
• Cancer patients: Develops in 3-5% of patients with lung cancer and 2-4% of patients with non-Hodgkin lymphoma [4]
• Age distribution: Peak incidence in 6th-7th decades, reflecting predominance of malignant causes [3]
• Sex ratio: Male predominance (2-3:1) due to higher lung cancer incidence [9]

Aetiological Distribution

Temporal Trends

The epidemiology of SVCS has shifted over the past three decades:

• 1950s-1980s: Malignant causes comprised > 95% of cases, with syphilitic aortic aneurysm historically prevalent [12]
• 1990s-2000s: Rise in benign catheter-related cases with increased use of indwelling central venous devices [5]
• 2010s-present: Cardiac implantable electronic device (CIED) leads now account for 30-40% of benign cases [13,14]
• Recent data: Studies report benign aetiologies in up to 40% of contemporary SVCS cases, with thrombotic mechanisms predominating [15]

Aetiology and Pathophysiology

Anatomical Considerations

The SVC is a thin-walled, low-pressure vessel formed by the confluence of the right and left brachiocephalic veins, measuring 7-8 cm in length and 1.5-2.0 cm in diameter. [1] It courses through the right anterior mediastinum within the confined space bounded by the trachea, aorta, pulmonary artery, and right mainstem bronchus, before entering the right atrium. This anatomical position makes the SVC vulnerable to compression by mediastinal masses and adjacent lymph nodes.

The surrounding rigid structures (sternum, trachea, right mainstem bronchus, aorta) prevent the SVC from expanding when external compression occurs, leading to impaired venous return. The thin vessel wall (1 mm) offers minimal resistance to external pressure from tumours or lymphadenopathy. [16]

Aetiological Classification

Malignant Causes (60-85%)

Lung Cancer (50-81% of malignant SVCS) [2,4]

• Small cell lung cancer: 35-50% of malignant SVCS; right upper lobe tumours with mediastinal nodal involvement
• Non-small cell lung cancer: 30-46%; predominantly squamous cell and adenocarcinoma with mediastinal extension
• Mechanisms: Direct tumour invasion, extrinsic compression by mediastinal lymphadenopathy, tumour thrombus

Lymphoma (2-21% of malignant SVCS) [4]

• Non-Hodgkin lymphoma: Diffuse large B-cell lymphoma, lymphoblastic lymphoma, primary mediastinal B-cell lymphoma
• Hodgkin lymphoma: Nodular sclerosing subtype with anterior mediastinal involvement
• Mechanism: Bulky mediastinal mass causing extrinsic compression

Other Malignancies (5-10%) [17]

• Thymoma and thymic carcinoma
• Germ cell tumours (seminoma, non-seminomatous germ cell tumours)
• Metastatic disease: Breast cancer, colon cancer, melanoma, sarcoma
• Mediastinal mesothelioma

Benign Causes (15-40%)

Thrombotic (30-35% of all SVCS) [5,6,15]

Central Venous Catheter-Related [18]

• Peripherally inserted central catheters (PICCs): 0.3-28.3% thrombosis rate
• Tunnelled central lines (e.g., Hickman, Port-a-Cath): 5-12% thrombosis rate
• Haemodialysis catheters: 10-50% thrombosis rate depending on catheter type and duration
• Risk factors: Catheter tip malposition, prolonged dwell time, multiple catheter insertions, thrombophilia, parenteral nutrition, chemotherapy

Cardiac Implantable Electronic Device Leads [13,14]

• Pacemaker leads: Thrombosis in 30-50% (subclinical), symptomatic SVCS in 0.3-3.5%
• ICD leads: Higher thrombosis risk due to larger lead diameter
• Lead abandonment: Cumulative risk increases with number of abandoned leads
• Risk factors: Multiple leads, left-sided implantation, lead diameter > 2.5 mm, dual-coil ICD leads

Non-Thrombotic Benign (2-5%) [10]

Fibrosing Mediastinitis [19]

• Aetiology: Histoplasma capsulatum (most common in endemic areas), tuberculosis, sarcoidosis, autoimmune disorders, idiopathic
• Mechanism: Progressive fibrosis and calcification causing SVC encasement
• Clinical course: Gradual onset with extensive collateral development

Other Benign Causes

• Substernal goitre: Retrosternal thyroid extension causing SVC compression
• Aortic aneurysm: Thoracic aortic aneurysm (now rare with declining syphilis incidence)
• Benign thymic lesions: Thymolipoma, thymic hyperplasia
• Idiopathic sclerosing mediastinitis

Pathophysiology

Haemodynamic Consequences

Normal SVC Physiology

• Blood flow: 2,000-3,000 mL/min at rest [1]
• Pressure: 2-8 mmHg (low-pressure system)
• Drainage: Head, neck, upper extremities, upper thorax via brachiocephalic veins

Obstruction Pathophysiology

When SVC flow is obstructed, central venous pressure rises proximal to the obstruction (typical elevation to 20-40 mmHg). [20] This elevated pressure is transmitted retrograde through the brachiocephalic veins, internal jugular veins, subclavian veins, and their tributaries, resulting in:

1. Increased capillary hydrostatic pressure: Fluid extravasation into interstitial space (facial/upper extremity oedema)
2. Elevated cerebral venous pressure: Risk of cerebral oedema, increased intracranial pressure, rarely cerebral venous infarction [21]
3. Laryngeal and upper airway oedema: Potential airway compromise in severe cases [7]
4. Reduced cardiac preload: Decreased venous return can reduce cardiac output in acute obstruction

Collateral Circulation Development

The development of collateral venous pathways determines symptom severity and tempo. Four major collateral systems exist: [22]

1. Azygos system: Most important; drains to IVC via azygos and hemiazygos veins
2. Internal mammary veins: Connect to superficial epigastric/inferior epigastric veins
3. Lateral thoracic veins: Connect to superficial abdominal wall veins
4. Vertebral venous plexus: Drains to epidural veins and IVC

Tempo of Obstruction

• Acute obstruction (hours to days): Insufficient collateral development; severe symptoms including cerebral oedema, airway compromise (rare but life-threatening)
• Subacute obstruction (weeks): Moderate symptoms as collaterals develop
• Chronic obstruction (months): Extensive collateral networks; minimal symptoms despite complete SVC occlusion

Exam Detail: Molecular and Cellular Mechanisms of Thrombosis

Central venous catheter-associated thrombosis involves multiple mechanisms based on Virchow's triad:

Endothelial Injury [18]

• Catheter insertion trauma: Direct vessel wall damage activating tissue factor pathway
• Chronic irritation: Catheter-induced endothelial denudation exposes subendothelial collagen
• Inflammatory response: Cytokine release (IL-1β, IL-6, TNF-α) promotes procoagulant endothelial phenotype

Stasis and Flow Disruption

• Catheter tip malposition: Tip abutting vessel wall creates low-flow zone
• Flow obstruction: Large-bore catheters reduce SVC cross-sectional area by 30-50%
• Fibrin sheath formation: Catheter coating by fibrin within 24-48 hours; serves as thrombogenic nidus

Hypercoagulability

• Cancer-associated thrombosis: Tissue factor expression, platelet activation, impaired fibrinolysis
• Chemotherapy effects: L-asparaginase depletes antithrombin; cisplatin damages endothelium
• Parenteral nutrition: Lipid infusions activate coagulation cascade
• Inherited thrombophilia: Factor V Leiden, prothrombin G20210A mutation increase risk 2-3 fold

Lead-Induced Thrombosis Mechanisms [13,14]

• Lead endothelialisation: Incorporation into vessel wall over 6-12 months
• Endothelial disruption: Lead motion with cardiac cycle causes chronic vessel injury
• Lead number: Each additional lead increases thrombosis risk by 40-60%
• Lead surface area: Larger diameter and dual-coil ICD leads have greater thrombogenic potential

Clinical Presentation

Symptom Onset and Tempo

The rate of symptom development reflects the aetiology and correlates with severity:

• Acute onset (less than 2 weeks): Suggests thrombotic occlusion (catheter/device-related); higher risk of airway/cerebral complications [7]
• Subacute onset (2-4 weeks): Typical of aggressive malignancies (SCLC, lymphoma)
• Gradual onset (> 4 weeks): Suggests slowly growing tumour or fibrosing mediastinitis with extensive collateral formation [19]

Cardinal Symptoms

Physical Examination Findings

Inspection

• Facial plethora: Violaceous discolouration and oedema of face, neck, conjunctival oedema
• Facial/periorbital oedema: Non-pitting; worse in morning; improves with upright position
• Neck vein distension: Non-pulsatile jugular venous distension; JVP not assessable due to obstruction
• Upper extremity oedema: Bilateral arm swelling; unilateral if isolated brachiocephalic vein obstruction
• Collateral vein pattern: Dilated veins on chest wall, neck, abdomen (flow direction determines level of obstruction)

Palpation

• Supraclavicular lymphadenopathy: Suggests malignancy with nodal involvement
• Neck mass: Thyroid goitre, lymphadenopathy, or other mediastinal mass extension

Special Tests

Pemberton Sign [26]

• Technique: Patient raises both arms above head for 1-2 minutes
• Positive sign: Facial plethora, venous engorgement, dyspnoea, stridor develop within 1 minute
• Mechanism: Arm elevation further compresses SVC in thoracic inlet by raising clavicles and narrowing thoracic outlet
• Interpretation: Positive sign suggests significant SVC or thoracic inlet obstruction; sensitivity 78%, specificity 85% for SVCS [26]
• False positives: Retrosternal goitre without SVCS, severe aortic regurgitation, superior mediastinal mass without vascular involvement

Clinical Pearl: Pemberton Sign Assessment Tips

• Position patient seated upright for standardised assessment
• Observe for facial flushing (earliest sign, appears within 15-30 seconds in true SVCS)
• Listen for inspiratory stridor (indicates severe obstruction with laryngeal oedema)
• Test can precipitate acute respiratory distress in severe SVCS; have oxygen and airway equipment available
• Negative Pemberton sign does not exclude SVCS; sensitivity only 78% [26]
• In malignant SVCS with slow onset and collateral development, Pemberton sign may be negative despite complete SVC occlusion

Red Flag Features (Potentially Life-Threatening)

These features indicate severe obstruction requiring urgent assessment: [7,8]

• Stridor: Laryngeal oedema; impending airway obstruction
• Altered consciousness: Cerebral oedema or venous infarction
• Severe dyspnoea at rest: Respiratory compromise
• Facial or tongue swelling: Risk of airway obstruction
• Seizures: Cerebral venous hypertension
• Syncope: Reduced cardiac output from severely impaired venous return
• Acute symptom onset (less than 2 weeks): Insufficient collateral development; higher complication risk

Exam Detail: Grading Severity: Kishi Scoring System [27]

A validated scoring system stratifies SVCS severity based on clinical features (rarely used in routine practice but asked in exams):

Differential Diagnosis

SVCS must be distinguished from other causes of facial/upper body swelling and dyspnoea:

Primary Differentials

Critical "Must Not Miss" Diagnoses

1. Acute SVCS with airway compromise: Requires immediate airway assessment and intervention [7]
2. Cardiac tamponade: Malignant pericardial effusion may coexist with SVCS in lung cancer/lymphoma; hypotension, muffled heart sounds, pulsus paradoxus [28]
3. Pulmonary embolism: May coexist with SVCS in malignancy; acute dyspnoea, pleuritic chest pain, hypoxia [29]
4. Tension pneumothorax: Can occur with mediastinal mass biopsy or central line insertion; sudden deterioration, absent breath sounds, tracheal deviation [30]

Investigations

Diagnostic Approach: Tissue Diagnosis Priority

Evidence Debate: Historical Perspective vs Modern Evidence-Based Practice

Historical Approach (Pre-1990s)

• SVCS historically considered an oncological emergency requiring immediate radiation therapy without tissue diagnosis [12]
• Rationale: Perceived high risk of biopsy complications (bleeding, airway compromise during sedation)
• Consequence: 3-17% of patients treated empirically were subsequently found to have benign disease [8]

Evidence for Tissue Diagnosis First (Current Standard) [7,8,31]

Armstrong et al. (1987) landmark study demonstrated: [8]

• 99/107 patients (93%) successfully underwent tissue diagnosis procedures without complications
• Diagnosis altered management in 26% of cases
• Only 8/107 (7.5%) required emergency treatment before diagnosis
• No procedure-related deaths

Rowell and Gleeson (2002) systematic review: [7]

• SVCS rarely life-threatening; mortality from acute complications less than 3%
• Tissue diagnosis alters cancer subtype in 20-40% of cases
• Treatment success depends on accurate histological diagnosis and stage
• Biopsy complication rate in SVCS: 1-2% (similar to non-SVCS patients)

Current Recommendation: Obtain tissue diagnosis before initiating treatment in > 90% of cases; exceptions limited to severe airway compromise or cerebral oedema unresponsive to medical therapy [31,32]

Initial Assessment

Clinical Evaluation

• Detailed history: Smoking, malignancy history, central venous catheter/cardiac device, dysphagia, weight loss
• Symptom tempo: Acute (less than 2 weeks), subacute (2-4 weeks), chronic (> 4 weeks)
• Physical examination: Pemberton sign, collateral venous pattern, lymphadenopathy, signs of malignancy

First-Line Investigations (All Patients)

1. Chest X-ray (Posteroanterior and Lateral) [33]

   • Findings: Widened superior mediastinum (85%), right hilar mass (45%), pleural effusion (25%)
   • May show normal chest X-ray in 16% of SVCS cases (especially catheter-related thrombosis)
   • Utility: Rapid, widely available; guides further imaging

2. Contrast-Enhanced CT Chest (Venous Phase) [34,35]

   • Gold standard imaging modality for SVCS diagnosis and aetiology determination
   • Sensitivity: 96-100% for detecting SVC obstruction [35]
   • Protocol: CT venography with delayed venous phase (60-90 seconds post-contrast) optimises SVC and collateral vessel opacification
   • Provides: Level and extent of obstruction, presence of thrombus vs external compression, collateral pathways, mediastinal mass characteristics, lymphadenopathy
   • Identifies biopsy targets: Accessible lymph nodes, pleural/pericardial involvement

3. Routine Bloods

   • Full blood count: Anaemia (chronic disease/malignancy), thrombocytosis (paraneoplastic), leukocytosis (infection, leukaemia)
   • Renal function: Baseline before contrast imaging
   • Liver function tests: Hepatic metastases
   • Coagulation screen: Baseline before biopsy; assess bleeding risk if anticoagulation considered
   • Lactate dehydrogenase (LDH): Elevated in lymphoma, germ cell tumours

Tissue Diagnosis Methods

The choice of biopsy technique depends on anatomical accessibility, patient stability, and local expertise: [31,36]

Bronchoscopy with Endobronchial Biopsy/TBNA [36]

• Indications: Visible endobronchial lesion, peribronchial mass, subcarinal lymphadenopathy
• Diagnostic yield: 50-70% for lung cancer with endobronchial involvement
• Technique: Conventional bronchoscopy with endobronchial biopsy; transbronchial needle aspiration (TBNA) for subcarinal nodes
• Complications: Bleeding (1-5%), pneumothorax (rare in endobronchial biopsy)
• Advantage: Well-tolerated; visualises airway; can assess tracheal/bronchial compression

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) [37]

• Indications: Mediastinal/hilar lymphadenopathy; peribronchial mass
• Diagnostic yield: 85-95% for mediastinal staging and tissue diagnosis in lung cancer
• Technique: Real-time ultrasound guidance for mediastinal node sampling (stations 2R, 2L, 4R, 4L, 7)
• Complications: less than 2% major complications; very low bleeding risk
• Advantage: High diagnostic yield; minimal invasiveness; suitable for SVCS patients

Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) [38]

• Indications: Posterior mediastinal masses, subcarinal nodes, aortopulmonary window nodes (station 5, 6), left adrenal masses
• Diagnostic yield: 90-95% for posterior mediastinal lymph nodes
• Technique: Transgastric/transesophageal approach with real-time ultrasound guidance
• Advantage: Complementary to EBUS; accesses posterior stations (8, 9)
• Evidence: Black and Eloubeidi (2007) reported successful EUS-FNA diagnosis in SVCS with 100% diagnostic accuracy and no complications [38]

CT-Guided Transthoracic Needle Biopsy [39]

• Indications: Peripheral lung masses, anterior mediastinal masses (thymoma, germ cell tumours), pleural masses
• Diagnostic yield: 85-95% for malignant lesions
• Complications: Pneumothorax (15-25%, chest drain required in 5-10%), haemorrhage (5%)
• Contraindications: Severe respiratory compromise (cannot tolerate pneumothorax)

Mediastinoscopy [40]

• Indications: Accessible anterior/superior mediastinal masses when less invasive methods non-diagnostic
• Diagnostic yield: > 95% with larger tissue samples for histology and immunohistochemistry
• Technique: Cervical mediastinoscopy for stations 2, 4, 7; anterior mediastinotomy (Chamberlain procedure) for stations 5, 6
• Complications: Bleeding (1-3%), recurrent laryngeal nerve injury (less than 1%), pneumothorax (1-2%)
• Considerations: Requires general anaesthesia; higher risk in severe SVCS with venous distension

Supraclavicular/Cervical Lymph Node Biopsy [41]

• Indications: Palpable supraclavicular or cervical lymphadenopathy
• Technique: Ultrasound-guided FNA or excisional biopsy
• Diagnostic yield: 85-90% for metastatic carcinoma; > 95% for lymphoma (excisional biopsy preferred for architecture)
• Advantage: Least invasive; local anaesthesia; no mediastinal instrumentation

Pleural Fluid Analysis/Pleural Biopsy [42]

• Indications: Moderate-to-large pleural effusion
• Diagnostic yield: Cytology 60-70% for malignant effusion; image-guided pleural biopsy 80-90%
• Technique: Ultrasound-guided thoracentesis; send fluid for cytology, biochemistry (LDH, protein), microbiological culture if infection suspected
• Advantage: Rapid; therapeutic (relieves dyspnoea); safe

Clinical Pearl: Selecting the Optimal Biopsy Approach in SVCS

Step 1: Review CT chest

• Pleural effusion present → Diagnostic thoracentesis first (easiest, safest)
• Palpable lymph nodes → Ultrasound-guided FNA (minimally invasive)
• Endobronchial lesion → Bronchoscopy with biopsy
• Mediastinal lymphadenopathy → EBUS-TBNA first-line (high yield, low risk)
• Anterior mediastinal mass (thymoma, germ cell tumour) → CT-guided biopsy or mediastinoscopy
• Posterior mediastinal mass → EUS-FNA

Step 2: Consider patient factors

• Severe respiratory compromise → Avoid procedures requiring general anaesthesia; prefer EBUS, EUS, or supraclavicular FNA
• Coagulopathy → Correct before invasive procedures; prefer least vascular routes (pleural fluid, lymph node FNA)
• Need for extensive tissue (lymphoma subtyping, immunohistochemistry) → Excisional biopsy (lymph node) or mediastinoscopy over FNA

Step 3: Institutional expertise

• Use the technique with highest local diagnostic yield and safety record

Definitive Vascular Imaging

Venography (Conventional or CT/MR Venography) [43]

• Indications: Planning endovascular intervention (stent placement); delineating collateral circulation; assessing thrombus extent
• Technique:
  • "CT venography: Contrast-enhanced CT with venous phase acquisition"
  • "MR venography: Time-of-flight or contrast-enhanced sequences (avoid gadolinium in renal impairment)"
  • "Conventional venography: Invasive; contrast injection via upper extremity veins; performed during intervention"
• Provides: Precise anatomical detail of SVC, brachiocephalic veins, azygos system; differentiates external compression from intrinsic thrombosis; assesses suitability for stenting

Duplex Ultrasound [44]

• Limited role: Assesses jugular/subclavian veins for thrombosis; cannot visualise SVC due to bony structures
• Utility: Identifies upper extremity deep vein thrombosis (DVT) associated with catheter-related SVCS

Additional Investigations Based on Aetiology

If Malignancy Suspected

• Tumour markers: β-hCG, AFP (germ cell tumours); LDH (lymphoma, SCLC)
• Sputum cytology: Low yield (15-20%); non-invasive option if biopsy not possible
• Bone marrow biopsy: If lymphoma/leukaemia suspected and other sites inaccessible
• PET-CT: Staging once diagnosis established; identifies distant metastases

If Thrombotic Cause Suspected [45]

• Upper extremity venous duplex ultrasound: Assess jugular, subclavian, axillary veins
• Review catheter history: Type, duration, complications
• Thrombophilia screen (selected cases): Factor V Leiden, prothrombin G20210A, protein C/S, antithrombin if recurrent thrombosis, family history, or young age (less than 50)

If Fibrosing Mediastinitis Suspected [19]

• Histoplasma serology and urine antigen: Endemic areas (Ohio/Mississippi river valleys)
• Tuberculin skin test or interferon-gamma release assay (IGRA): TB exposure
• Autoimmune screen: ANA, anti-dsDNA, complement (if systemic autoimmune disease suspected)

Classification and Grading

Anatomical Classification by Level of Obstruction

The site of obstruction influences symptom pattern and collateral development:

Type 1: Bilateral Brachiocephalic Vein Obstruction

• Bilateral upper limb oedema
• Severe facial oedema
• Extensive collateral network required
• Poorest prognosis for collateral compensation

Type 2: Superior Vena Cava Obstruction (Above Azygos Junction)

• Facial and upper extremity oedema
• Collaterals via azygos system ineffective (azygos vein also obstructed)
• Requires development of anterior chest wall and vertebral plexus collaterals

Type 3: Superior Vena Cava Obstruction (Below Azygos Junction)

• Azygos vein remains patent; most effective collateral drainage
• Better symptom control
• Lower intracranial pressure

Type 4: Unilateral Brachiocephalic Vein Obstruction

• Ipsilateral upper limb oedema
• Minimal facial swelling (contralateral drainage preserved)
• Best prognosis; often asymptomatic with collaterals

Stanford Classification by Aetiology [46]

Management

The management of SVCS is aetiology-dependent. Historical emergency radiation therapy has been replaced by evidence-based approaches prioritising tissue diagnosis and targeted therapy.

General Supportive Measures (All Patients)

Conservative Management [47]

• Head elevation: 30-45 degrees in bed; reduces venous pressure and facial oedema
• Oxygen therapy: Maintain SpO₂ > 92%; nasal cannula or face mask
• Avoidance of venepuncture/cannulation in upper limbs: Prevents exacerbation of venous hypertension and thrombosis; use femoral or lower extremity access if required
• Fluid restriction: Mild restriction (1.5-2 L/day) in severe oedema
• Low-salt diet: Reduces fluid retention

Pharmacological Symptom Relief

Corticosteroids [48]

• Indications: Lymphoma-related SVCS (tumour lysis prevention); laryngeal oedema; cerebral oedema
• Regimen: Dexamethasone 8-16 mg/day orally or IV (divided doses) for 3-7 days
• Evidence: Modest symptom improvement in 60-70% within 48-72 hours in lymphoma; limited efficacy in lung cancer-related SVCS [48]
• Caution: May obscure histological diagnosis in lymphoma; delay initiation until after tissue sampling if possible (discuss with oncology/haematology)

Diuretics [47]

• Indications: Significant oedema causing discomfort; fluid overload
• Regimen: Furosemide 40-80 mg oral/IV once or twice daily
• Caution: Risk of volume depletion and reduced cardiac output in acute severe SVCS; monitor fluid balance

Anticoagulation [45,49]

• Indications: Thrombotic SVCS (catheter-related, lead-related); prevent thrombus propagation
• Contraindications: Active bleeding, severe thrombocytopenia (less than 50 × 10⁹/L), recent CNS haemorrhage, planned high-risk procedure
• Initial therapy: Low molecular weight heparin (LMWH) preferred over unfractionated heparin
  • Enoxaparin 1 mg/kg subcutaneous twice daily OR 1.5 mg/kg once daily
  • Dalteparin 200 units/kg subcutaneous once daily
• Long-term therapy: Direct oral anticoagulants (DOACs) or vitamin K antagonists (warfarin target INR 2-3)
  • "Duration: Minimum 3-6 months; consider indefinite if catheter remains in situ or malignancy present [45]"
• Evidence: Anticoagulation reduces recurrent thrombosis and post-thrombotic syndrome; no RCT data specific to SVCS, extrapolated from DVT/PE trials

Emergency Management (Severe/Life-Threatening SVCS)

Indications for Emergency Treatment (WITHOUT awaiting tissue diagnosis) [7,8]:

• Stridor or impending airway obstruction
• Altered consciousness from cerebral oedema
• Seizures
• Haemodynamic instability

Emergency Interventions

1. Airway Management

   • High-flow oxygen; consider non-invasive ventilation (CPAP/BiPAP)
   • Early anaesthetic/ICU involvement if intubation may be required
   • Caution: Positive pressure ventilation can worsen venous return; intubation high-risk in SVCS due to venous engorgement and bleeding risk

2. Corticosteroids

   • Dexamethasone 16 mg IV loading, then 8 mg every 6-8 hours
   • Reduces laryngeal and cerebral oedema within 6-12 hours

3. Urgent Endovascular Stenting [50,51]

   • Indicated in life-threatening SVCS when immediate decompression required
   • Symptom improvement within 24-72 hours in 85-95% [50]
   • Can be performed before tissue diagnosis; allows stabilisation followed by diagnostic biopsy

4. Empirical Chemotherapy/Radiation (ONLY if tissue diagnosis impossible and life-threatening)

   • Small cell lung cancer or lymphoma most likely if young, mediastinal mass, elevated LDH
   • Platinum-based chemotherapy or urgent radiation therapy (dose: 3-4 Gy × 2-3 fractions as emergency measure)

Definitive Management by Aetiology

Malignant SVCS

Small Cell Lung Cancer [52]

• First-line: Combination chemotherapy (platinum + etoposide); 77% response rate
• Radiotherapy: Reserved for chemotherapy-refractory disease or combined modality treatment (concurrent chemoradiation)
• SVCS symptom resolution: 60-85% within 2-4 weeks of chemotherapy [52]
• Evidence: Chemotherapy superior to radiation alone for SCLC-related SVCS (higher response rate, treats systemic disease)

Non-Small Cell Lung Cancer [53]

• Treatment depends on stage:
  • "Early-stage (I-II): Surgery if resectable after neoadjuvant therapy"
  • "Locally advanced (III): Concurrent chemoradiation"
  • "Metastatic (IV): Systemic therapy (chemotherapy, targeted therapy if EGFR/ALK mutation, immunotherapy)"
• Radiotherapy for SVCS: Palliative radiation (30 Gy in 10 fractions or 20 Gy in 5 fractions) if systemic therapy delayed
• Symptom improvement: 70-90% within 2-4 weeks [53]

Non-Hodgkin Lymphoma [54]

• First-line: Combination chemotherapy (R-CHOP for DLBCL; hyperfractionated chemotherapy for lymphoblastic lymphoma)
• SVCS response: 80-95% within 1-2 weeks (lymphoma highly chemosensitive)
• Radiotherapy role: Consolidation after chemotherapy in selected cases; not first-line for SVCS in lymphoma
• Caution: Corticosteroids can obscure diagnosis; obtain tissue before initiating steroids if possible

Germ Cell Tumours [55]

• First-line: Platinum-based chemotherapy (BEP: bleomycin, etoposide, cisplatin)
• Response: Excellent; 80-90% SVCS resolution within 2-3 weeks
• Surgery: Post-chemotherapy resection of residual mediastinal mass if viable tumour or teratoma

Role of Radiotherapy in Malignant SVCS [56,57]

Evidence Debate: Radiation Therapy Timing: Immediate vs Delayed

Historical Practice: Immediate emergency radiation (often initiated within hours of presentation) [12]

Modern Evidence:

Rowell and Gleeson (2002): [7]

• Systematic review of 1,986 SVCS patients
• Only 3% had life-threatening symptoms requiring emergency treatment
• Delaying radiation to obtain tissue diagnosis did not worsen outcomes
• 20-40% of patients had diagnosis changed after biopsy, altering management

Chan (1997): [56]

• Retrospective analysis of 125 lung cancer patients with SVCS
• No survival difference between immediate radiation vs delayed radiation after chemotherapy
• Symptom relief comparable with either approach (median 7-10 days to improvement)

Current Recommendation [31,57]:

• Defer radiation until tissue diagnosis obtained (unless life-threatening features)
• Indications for radiotherapy in malignant SVCS:
  • NSCLC when chemotherapy/targeted therapy ineffective or delayed
  • Refractory SCLC after chemotherapy
  • Consolidation after chemotherapy in lymphoma (selected cases)
  • Palliation in poor-performance status patients unsuitable for systemic therapy
• Typical regimens:
  • "Radical intent: 60-66 Gy in 2 Gy fractions (concurrent with chemotherapy for NSCLC)"
  • "Palliative: 30 Gy in 10 fractions or 20 Gy in 5 fractions"
  • "Hypofractionated: 17 Gy in 2 fractions (if prognosis less than 3 months)"
• Symptom improvement: 70-95% of patients improve within 2 weeks [56,57]

Benign Thrombotic SVCS

Catheter-Related and Device-Related Thrombosis [45,49,58]

Step 1: Assess Catheter/Device Necessity

• If catheter no longer required → Remove
• If catheter essential (ongoing chemotherapy, TPN, haemodialysis) → Consider retention with anticoagulation ± stenting
• If pacemaker/ICD leads → Assess device necessity; lead extraction vs anticoagulation ± stenting

Step 2: Anticoagulation [45]

• Initiate immediately (unless contraindications)
• Acute phase: LMWH or fondaparinux for minimum 5-7 days
  • Enoxaparin 1 mg/kg SC twice daily
  • Dalteparin 200 units/kg SC once daily (maximum 18,000 units)
  • Fondaparinux 7.5 mg SC once daily (5 mg if less than 50 kg; 10 mg if > 100 kg)
• Long-term therapy:
  • DOACs (rivaroxaban, apixaban, edoxaban) preferred over warfarin for convenience; avoid in severe renal impairment (CrCl less than 30)
  • Warfarin (INR 2-3) if DOAC contraindicated
  • "Duration: "
    • Minimum 3 months if catheter removed
    • 3-6 months if catheter remains but functional
    • Indefinite if catheter permanent or malignancy present [45]

Step 3: Consider Thrombolysis [59]

• Indications: Acute thrombosis (less than 14 days), severe symptoms, failed anticoagulation
• Catheter-directed thrombolysis (CDT): Delivers thrombolytic agent directly into thrombus via catheter
  • "Agents: Tissue plasminogen activator (tPA) 0.5-1 mg/hour for 12-24 hours"
  • "Success rate: 60-85% thrombus dissolution [59]"
  • "Complications: Major bleeding 5-10%; intracranial haemorrhage 0.5-1%"
• Systemic thrombolysis: Higher bleeding risk; rarely used for SVCS (reserved for massive PE)
• Contraindications: Recent surgery (less than 10 days), active bleeding, recent stroke, brain metastases

Step 4: Endovascular Stenting [50,51,60]

Indications for SVC Stenting in Benign Disease [60]

• Severe symptoms despite anticoagulation
• Recurrent thrombosis despite anticoagulation
• Chronic SVC occlusion with inadequate collaterals
• Contraindication to anticoagulation

Technique

• Performed by interventional radiology or vascular surgery
• Access: Femoral vein or internal jugular vein approach
• Venography: Delineate occlusion extent and collaterals
• Angioplasty: Balloon dilation before stent deployment (if chronic occlusion)
• Stent type: Self-expanding stainless steel or nitinol stents; diameter 14-20 mm; length to cover entire stenosis
• Post-procedure: Anticoagulation continued indefinitely (minimum 6-12 months)

Outcomes of SVC Stenting in Benign Disease [60,61]

• Technical success: 90-95%
• Symptom improvement: 85-95% within 24-72 hours
• Primary patency: 75-85% at 1 year, 60-70% at 5 years
• Re-intervention rate: 20-30% (for in-stent stenosis/thrombosis)
• Complications: Migration (2-5%), stent thrombosis (5-10%), perforation (less than 1%), pulmonary embolism (rare if stent migrates)

Post-Stent Anticoagulation Debate [62]

Evidence Debate: Duration of Anticoagulation After SVC Stenting in Benign Disease

Controversy: No consensus on anticoagulation duration post-stent placement for benign SVCS.

Arguments for Long-Term/Indefinite Anticoagulation [62]:

• Stent creates thrombogenic surface; risk of in-stent thrombosis
• Underlying prothrombotic state often persists (catheter in situ, lead burden)
• Haddad et al. (2018) retrospective study: [62]
  • 43 patients with benign SVCS treated with stent; median follow-up 46 months
  • "No anticoagulation: 40% re-occlusion rate"
  • "Anticoagulation (indefinite): 8% re-occlusion rate (p=0.03)"
  • "Recommendation: Indefinite anticoagulation improves stent patency"

Arguments for Time-Limited Anticoagulation [51]:

• Bleeding risk with long-term anticoagulation (1-3% major bleeding/year)
• Stent endothelialises over 6-12 months, reducing thrombogenicity
• Some patients remain asymptomatic despite re-stenosis due to collaterals

Current Practice [60,62]:

• Minimum duration: 6-12 months anticoagulation post-stent
• Indefinite anticoagulation recommended if:
  • Catheter/device remains in situ
  • Recurrent thrombosis history
  • Thrombophilia present
  • Poor collateral development (high re-occlusion symptom risk)
• Individualised decision: Balance thrombosis vs bleeding risk

Lead Extraction [13,14]

• Indications:
  • Infected leads
  • Non-functional leads causing obstruction
  • Multiple abandoned leads with SVCS
• Technique: Percutaneous lead extraction using laser sheaths or mechanical sheaths
• Risks: SVC/cardiac perforation (1-2%), cardiac tamponade (0.5%), death (0.2-0.4%)
• Outcomes: SVCS symptom improvement in 60-70% if leads removed; 40-50% require additional stenting [13]

Benign Non-Thrombotic SVCS

Fibrosing Mediastinitis [19,63]

• Aetiology-specific treatment:
  • "Histoplasmosis: Antifungal therapy (itraconazole 200 mg twice daily for 6-12 months) in active infection; limited efficacy once fibrosis established"
  • "Tuberculosis: Standard anti-TB therapy (RIPE regimen)"
  • "Autoimmune/idiopathic: Corticosteroids + immunosuppression (azathioprine, mycophenolate) with limited evidence"
• Surgical intervention: Rarely feasible due to dense fibrosis and calcification; high morbidity/mortality
• Endovascular stenting: Preferred approach if symptoms severe; technical success 70-85% (lower than malignant/thrombotic SVCS due to fibrosis) [63]
• Prognosis: Chronic progressive course; symptom management and collateral development key

Retrosternal Goitre

• Treatment: Surgical resection (total thyroidectomy via cervical or sternotomy approach)
• Outcomes: Excellent; SVCS resolves post-operatively

Malignant SVCS: Endovascular Stenting

Indications for SVC Stenting in Malignant Disease [50,51,64]

• Severe symptoms requiring rapid relief
• Failed or delayed response to chemotherapy/radiation
• Extrinsic compression (stent provides mechanical scaffolding)
• Palliative care setting (rapid symptom control without prolonged treatment)

Outcomes in Malignant SVCS [64]

• Technical success: 95-100%
• Symptom improvement: 85-95% within 24-72 hours (faster than chemotherapy/radiation)
• Stent patency: 90% at 3 months, 80% at 6 months, 60% at 12 months
• Re-intervention: 10-20% require repeat procedures (angioplasty, re-stent)
• Complications: Migration (2-5%), fracture (1-3%), infection (less than 1%), haemorrhage (1-2%)

Combined Approach

• Stenting followed by chemotherapy/radiation provides optimal symptom control and durable response
• Stent prevents re-obstruction during initial weeks of systemic therapy

Stent Selection [65]

• Self-expanding stents (stainless steel or nitinol) preferred
• Diameter: 14-20 mm (individualised to SVC diameter)
• Length: Sufficient to cover entire obstruction + 1-2 cm proximal and distal
• Covered vs uncovered stents: Covered stents reduce tumour ingrowth but higher migration risk

Complications

Prognosis

Prognosis in SVCS is determined by the underlying aetiology rather than the obstruction itself.

Malignant SVCS

Small Cell Lung Cancer [52]

• Median survival: 6-12 months (limited-stage), 3-6 months (extensive-stage)
• SVCS resolution: Predicts better response to chemotherapy; median survival 10 months vs 4 months if SVCS persists [52]
• 2-year survival: 10-20% (limited-stage with chemoradiation), less than 5% (extensive-stage)

Non-Small Cell Lung Cancer [53]

• Median survival depends on stage:
  • "Stage IIIB (locally advanced): 12-18 months with chemoradiation"
  • "Stage IV (metastatic): 8-12 months with systemic therapy (higher if targetable mutations: EGFR, ALK)"
• Presence of SVCS: Indicates advanced disease; worse prognosis

Non-Hodgkin Lymphoma [54]

• Prognosis varies by subtype:
  • "DLBCL: 60-70% 5-year survival with R-CHOP"
  • "Lymphoblastic lymphoma: 50-60% 5-year survival with intensive chemotherapy"
• SVCS resolution: > 90% achieve complete resolution; does not independently affect prognosis

Germ Cell Tumours [55]

• Excellent prognosis: 80-90% cure rate with platinum-based chemotherapy
• SVCS: Indicates bulky disease but does not preclude cure

Benign SVCS

Catheter/Device-Related [60,66]

• With treatment: Excellent prognosis; > 80% symptom-free at 5 years with anticoagulation ± stenting
• Post-thrombotic syndrome: 20-30% develop chronic venous insufficiency despite treatment
• Stent patency: 60-70% primary patency at 5 years; re-intervention maintains symptom control

Fibrosing Mediastinitis [19,63]

• Progressive fibrosis: Chronic symptoms despite treatment
• Mortality: 5-year survival 80-90%; death usually from complications (haemoptysis, pulmonary hypertension) rather than SVCS

Factors Influencing Prognosis

Favourable Prognostic Factors

• Benign aetiology
• Gradual onset (> 4 weeks) allowing collateral development
• Chemosensitive malignancy (SCLC, lymphoma, germ cell tumours)
• Good performance status (ECOG 0-1)
• Response to initial therapy

Unfavourable Prognostic Factors

• Malignant aetiology (especially NSCLC, metastatic disease)
• Acute onset (less than 2 weeks) with inadequate collaterals
• Poor performance status (ECOG 3-4)
• Extensive metastatic disease
• Failure to respond to chemotherapy/radiation

Prevention and Screening

Primary Prevention

Reducing Catheter-Related SVCS Risk [18,67]

• Optimal catheter selection: Smallest gauge catheter appropriate for therapy
• Catheter tip positioning: Confirm tip in lower SVC or cavoatrial junction (NOT in brachiocephalic vein or upper SVC)
• Prophylactic anticoagulation: Controversial; not routinely recommended for cancer patients with central lines (low-quality evidence)
• Early catheter removal: Remove catheter as soon as no longer required

Reducing Lead-Related SVCS Risk [13,14]

• Lead extraction of non-functional leads: Remove abandoned leads rather than capping; reduces thrombosis risk
• Limit lead number: Dual-chamber pacing when single-chamber adequate; biventricular pacing only if indicated
• Anticoagulation: Not routinely recommended for CIED patients without other indications

Secondary Prevention (Preventing Recurrence)

Malignant SVCS

• Definitive oncological therapy: Chemotherapy/radiation reduces recurrence
• Stent placement: Prevents re-obstruction during chemotherapy/radiation
• Surveillance imaging: Monitor for tumour progression in high-risk patients

Benign Thrombotic SVCS

• Long-term anticoagulation: Reduces recurrent thrombosis (see anticoagulation section)
• Catheter removal: If possible
• Stent patency monitoring: Duplex ultrasound or CT venography if symptoms recur

Screening

No population-based screening recommended. SVCS is a clinical syndrome, not a disease entity; screening asymptomatic individuals is not indicated.

Key Guidelines and Consensus Statements

While no dedicated SVCS-specific international guidelines exist, management recommendations are derived from oncology, haematology, and vascular medicine guidelines:

National Comprehensive Cancer Network (NCCN) Guidelines [68]

• Lung cancer and non-Hodgkin lymphoma guidelines address SVCS management in context of specific malignancies
• Recommendation: Tissue diagnosis before treatment initiation unless life-threatening
• Stent placement considered for severe symptoms or delayed response to systemic therapy

American College of Chest Physicians (ACCP) Guidelines on Antithrombotic Therapy [45]

• Recommendation: Anticoagulation for catheter-related upper extremity DVT/SVCS for minimum 3 months
• DOAC or LMWH preferred over warfarin in cancer-associated thrombosis

British Thoracic Society (BTS) Guidelines [69]

• Management of lung cancer with SVCS: Diagnosis before treatment; stenting for severe symptoms
• Radiotherapy regimens: 30 Gy in 10 fractions or 20 Gy in 5 fractions for palliation

European Society of Medical Oncology (ESMO) Guidelines [70]

• SCLC with SVCS: Chemotherapy first-line; radiotherapy for refractory cases
• NSCLC with SVCS: Stage-appropriate treatment; stenting for symptom control

---

Exam-Focused Sections

Common Exam Questions

Written Exam (MCQ/SBA) High-Yield Topics

1. Most common cause of SVCS in contemporary practice (lung cancer vs catheter-related)
2. Pemberton sign: technique, interpretation, sensitivity/specificity
3. Tissue diagnosis priority vs emergency treatment
4. First-line imaging: CT chest with venous phase contrast
5. Stenting indications and outcomes in malignant vs benign SVCS
6. Anticoagulation duration post-stent in benign disease
7. Radiation therapy timing: modern evidence vs historical practice
8. Differentiating malignant vs benign causes on imaging

Clinical Exam (PACES, OSCE) Scenarios

• Recognising SVCS on examination: facial plethora, venous distension, collateral vessels
• Demonstrating Pemberton sign
• Formulating differential diagnosis for facial swelling
• Explaining investigation and management plan to patient
• Ethical discussion: emergency treatment vs awaiting biopsy

Viva Voce Questions

1. "Describe the anatomy of the SVC and explain why it is vulnerable to obstruction."
2. "A 65-year-old smoker presents with facial swelling and dyspnoea. How would you approach this?"
3. "What is the Pemberton sign and what does it indicate?"
4. "Discuss the evidence for tissue diagnosis before treatment in SVCS."
5. "Compare the management of malignant vs benign SVCS."
6. "When is endovascular stenting indicated in SVCS?"

Viva Points

Viva Point: Opening Statement for SVCS Viva

"Superior vena cava syndrome is a clinical syndrome caused by obstruction of the SVC, resulting in impaired venous drainage from the head, neck, and upper extremities. It presents with characteristic facial and upper body swelling, dyspnoea, and dilated collateral veins. The most common causes are lung cancer, particularly small cell lung cancer, accounting for 50-81% of malignant cases, and catheter-related thrombosis, which now represents 30-35% of all cases due to increasing use of central venous devices and cardiac leads."

Key Facts to Mention

1. Epidemiology: 15,000 cases/year in US; 60-85% malignant, 15-40% benign thrombotic [2,3,5]
2. Anatomy: SVC is thin-walled (1 mm), low-pressure vessel in confined mediastinal space; vulnerable to compression [1,16]
3. Collaterals: Four major systems (azygos, internal mammary, lateral thoracic, vertebral plexus); development tempo determines symptoms [22]
4. Pemberton sign: Arm elevation for 1 minute → facial plethora, venous engorgement; 78% sensitive, 85% specific [26]
5. Modern evidence: Tissue diagnosis priority (Armstrong 1987, Rowell 2002); only 3% require emergency treatment [7,8]
6. First-line imaging: Contrast-enhanced CT chest (venous phase); 96-100% sensitivity [34,35]
7. Malignant treatment: SCLC → chemotherapy first-line (77% response); radiation reserved for refractory disease [52]
8. Benign treatment: Anticoagulation ± stenting; indefinite anticoagulation post-stent improves patency (Haddad 2018) [62]
9. Stenting outcomes: 85-95% symptom improvement within 24-72 hours; malignant patency 60% at 1 year [50,64]
10. Prognosis: Determined by underlying aetiology; benign prognosis excellent (> 80% symptom-free at 5 years), malignant depends on cancer type [52-54,60]

Common Mistakes

Mistakes That Fail Candidates

❌ Stating SVCS is an oncological emergency requiring immediate radiation

• Modern evidence: Only 3% have life-threatening symptoms; tissue diagnosis should be obtained first in > 90% [7,8]

❌ Missing the Pemberton sign on examination

• This is a classic clinical sign; always perform when examining neck/venous system

❌ Recommending chest X-ray as definitive diagnostic test

• CXR has 16% false-negative rate; CT chest with contrast (venous phase) is gold standard [33-35]

❌ Failing to distinguish malignant from benign management

• Malignant: Chemotherapy/radiation (aetiology-specific); Benign thrombotic: Anticoagulation ± stenting

❌ Recommending thrombolysis for all thrombotic SVCS

• Thrombolysis reserved for acute (less than 14 days), severe, or anticoagulation-refractory cases; bleeding risk 5-10% [59]

❌ Not mentioning tissue diagnosis priority

• Critical concept: Tissue diagnosis before treatment improves outcomes; changes management in 20-40% [7,8,31]

❌ Confusing SVCS with heart failure

• SVCS: Facial > leg oedema, non-pulsatile JVP, collateral veins; HF: leg > facial oedema, pulsatile JVP, S3 gallop

❌ Stating corticosteroids are always first-line

• Steroids only indicated for lymphoma (risk of tumour lysis), laryngeal oedema, or cerebral oedema; limited efficacy in lung cancer [48]

Model Answers

Q1: A 60-year-old man presents with 2 weeks of progressive facial swelling and dyspnoea. On examination, there is facial plethora, dilated neck veins, and prominent chest wall veins. What is your approach?

Model Answer:

"This presentation is highly suggestive of superior vena cava syndrome. I would approach this systematically:

Initial Assessment: I would first assess for red flag features indicating life-threatening SVCS: stridor, altered consciousness, severe dyspnoea at rest, or facial/tongue swelling. I would perform the Pemberton sign—asking the patient to raise both arms above the head for 1 minute and observing for facial plethora, venous engorgement, or dyspnoea, which would support the diagnosis.

History: I would take a detailed history focusing on smoking (lung cancer risk), weight loss and constitutional symptoms (malignancy), presence of central venous catheters or cardiac devices (thrombotic SVCS), and tempo of symptom onset—acute (less than 2 weeks) suggests thrombosis, subacute (2-4 weeks) suggests aggressive malignancy like SCLC or lymphoma, chronic (> 4 weeks) suggests slow-growing tumour or fibrosing mediastinitis.

Investigations: My first-line investigation would be a contrast-enhanced CT chest with venous phase imaging, which has 96-100% sensitivity for detecting SVC obstruction and delineating the cause. I would also arrange basic bloods including FBC, renal function, liver function, LDH, and a coagulation screen.

Tissue Diagnosis Priority: Based on modern evidence from Armstrong (1987) and Rowell (2002), SVCS is rarely life-threatening—only 3% require emergency treatment. Tissue diagnosis should be obtained before initiating treatment in over 90% of cases, as this changes management in 20-40%. Depending on CT findings, I would arrange the most appropriate biopsy: EBUS-TBNA for mediastinal lymphadenopathy, CT-guided biopsy for peripheral masses, or pleural fluid cytology if an effusion is present.

Management: Supportive measures would include head elevation, oxygen therapy, and avoidance of upper limb venepuncture. Definitive treatment depends on aetiology: for malignancy, chemotherapy is first-line for SCLC and lymphoma with 77-95% response rates, while radiation is reserved for refractory disease; for thrombotic SVCS, anticoagulation with LMWH transitioning to a DOAC, with stenting considered if symptoms are severe or anticoagulation fails. Endovascular stenting provides rapid symptom relief in 85-95% within 24-72 hours and can be used in both malignant and benign severe cases."

Q2: What is the Pemberton sign and how is it performed?

Model Answer:

"The Pemberton sign is a clinical test to assess for superior vena cava obstruction or thoracic inlet obstruction. It is performed by asking the patient to raise both arms above their head for 1 to 2 minutes while seated upright. A positive sign is indicated by the development of facial plethora, facial and neck vein engorgement, dyspnoea, or stridor within 1 minute.

The mechanism involves arm elevation raising the clavicles and narrowing the thoracic outlet, which further compresses the SVC or thoracic inlet structures, exacerbating venous obstruction and increasing venous pressure in the head and neck.

The sign has a sensitivity of 78% and specificity of 85% for SVCS, as demonstrated in the literature. It is important to note that a negative Pemberton sign does not exclude SVCS, particularly in cases with gradual onset and extensive collateral development. False positives can occur with retrosternal goitre without vascular involvement or severe aortic regurgitation. The test should be performed with caution in severe SVCS as it can precipitate acute respiratory distress, and oxygen and airway equipment should be available."

Q3: Compare and contrast malignant SVCS from lung cancer versus benign thrombotic SVCS. How does your management differ?

Model Answer:

"Superior vena cava syndrome has distinct presentations and management approaches depending on whether the aetiology is malignant or benign thrombotic.

Comparison of Key Features:

Clinical Presentation: Malignant SVCS from lung cancer typically presents subacutely over 2-4 weeks, allowing some collateral development. Patients often have associated constitutional symptoms including weight loss, haemoptysis, and hoarseness from recurrent laryngeal nerve involvement. The onset correlates with tumour growth rate—small cell lung cancer progresses more rapidly than non-small cell lung cancer.

Benign thrombotic SVCS, conversely, often presents acutely over days to 2 weeks, particularly with catheter-related or lead-related thrombosis. The rapid onset means inadequate collateral formation and potentially more severe initial symptoms. However, patients lack systemic features of malignancy and typically have a clear history of central venous catheter or cardiac device placement.

Imaging Findings: On contrast-enhanced CT chest, malignant SVCS shows external compression of the SVC by mediastinal mass or lymphadenopathy, often with associated lung parenchymal abnormality, pleural effusion, or pericardial involvement. The vessel lumen is compressed but the wall remains smooth.

Benign thrombotic SVCS demonstrates intraluminal thrombus with expansion of the vessel diameter, filling defects within the SVC lumen, and often extension into brachiocephalic or jugular veins. The catheter or device leads are usually visible within the thrombosed vessel.

Management Approach:

For malignant lung cancer-related SVCS, tissue diagnosis is the absolute priority before treatment initiation. I would arrange the most appropriate biopsy based on CT findings—EBUS-TBNA for mediastinal nodes, bronchoscopy for endobronchial lesions, or CT-guided biopsy for peripheral masses. Supportive measures include head elevation and oxygen therapy. For severe symptoms requiring urgent relief, endovascular stenting provides symptom improvement in 85-95% within 24-72 hours and can be performed before tissue diagnosis if necessary.

Once histology is obtained, definitive treatment depends on cancer type. For small cell lung cancer, platinum-based combination chemotherapy is first-line with 77% SVCS response rates within 2-4 weeks. For non-small cell lung cancer, stage-appropriate treatment is initiated—surgery if resectable, chemoradiation for locally advanced disease, or systemic therapy for metastatic disease. Radiotherapy is reserved for refractory cases after chemotherapy fails, using palliative regimens such as 30 Gy in 10 fractions.

For benign thrombotic SVCS, anticoagulation is initiated immediately with low molecular weight heparin such as enoxaparin 1 mg/kg twice daily, transitioning to a direct oral anticoagulant for long-term therapy. The causative catheter is removed if no longer essential, though if required for ongoing treatment it can remain in situ with continued anticoagulation. For severe symptoms unresponsive to anticoagulation, endovascular stenting is considered. Post-stent, indefinite anticoagulation is recommended to maintain patency, as the Haddad 2018 study demonstrated only 8% re-occlusion with indefinite anticoagulation versus 40% without.

Prognosis:

Prognosis differs dramatically. Malignant SVCS from lung cancer has a median survival of 6-12 months for small cell lung cancer and 8-18 months for non-small cell lung cancer depending on stage, as prognosis is determined by the underlying malignancy rather than SVCS itself. SVCS resolution predicts better chemotherapy response and improved survival.

Benign thrombotic SVCS has excellent prognosis with appropriate treatment, with over 80% of patients symptom-free at 5 years. The main long-term concern is post-thrombotic syndrome in 20-30%, causing chronic venous insufficiency, but this is generally manageable with compression and does not affect survival."

Q4: A patient with newly diagnosed SVCS is hypoxic and tachypnoeic but has no stridor. The referring team wants to radiate immediately. How would you respond?

Model Answer:

"I would respectfully explain that while SVCS was historically considered an oncological emergency requiring immediate radiation, modern evidence demonstrates this approach is no longer appropriate in the vast majority of cases.

I would reference the landmark Armstrong 1987 study and the Rowell 2002 systematic review, which together showed that only 3% of SVCS cases are truly life-threatening with airway or cerebral complications. In 93% of cases, tissue diagnosis can be safely obtained without emergency treatment, and obtaining histology before radiation changes management in 20-40% of patients by identifying different cancer subtypes or even benign disease.

In this specific case, the patient has hypoxia and tachypnoea but no stridor, altered consciousness, or other red flag features indicating life-threatening complications. This suggests moderate SVCS that can be managed supportively while pursuing rapid diagnosis. I would initiate supportive measures immediately: sit the patient upright at 30-45 degrees, provide supplemental oxygen to maintain saturations above 92%, avoid upper limb venepuncture, and consider dexamethasone if lymphoma is suspected based on imaging.

Simultaneously, I would urgently arrange contrast-enhanced CT chest with venous phase to delineate the anatomy and identify biopsy targets. Based on the findings, I would facilitate same-day or next-day tissue diagnosis using the most appropriate technique—EBUS-TBNA for mediastinal lymphadenopathy has 85-95% diagnostic yield and can often be arranged urgently, EUS-FNA for posterior mediastinal masses, or CT-guided biopsy for peripheral lesions.

If symptoms deteriorate acutely with development of stridor or altered consciousness, endovascular stenting provides faster symptom relief than radiation therapy, with 85-95% improvement within 24-72 hours compared to 7-10 days for radiation. Stenting can be performed as a bridge to allow stabilisation before tissue diagnosis.

Only if tissue diagnosis is truly impossible despite multiple attempts, and the patient develops life-threatening features unresponsive to stenting, would I consider empirical treatment. Even then, I would discuss with oncology whether empirical chemotherapy might be more appropriate than radiation if the imaging appearances suggest small cell lung cancer or lymphoma, as these are more chemosensitive.

The key message is that radiation therapy timing should be determined by histology and cancer type rather than SVCS presence, as treatment efficacy depends on accurate diagnosis. Small cell lung cancer responds better to chemotherapy than radiation for SVCS, while non-small cell lung cancer treatment depends on stage and molecular profile. Radiating without diagnosis risks treating the wrong cancer with the wrong modality, compromising long-term outcomes."

Q5: Describe the collateral venous drainage pathways in SVCS and explain how their development affects clinical presentation.

Model Answer:

"The superior vena cava normally drains 2,000-3,000 mL of blood per minute from the head, neck, upper extremities, and upper thorax into the right atrium. When SVC obstruction occurs, four major collateral venous systems develop to bypass the obstruction and maintain venous return to the heart. The extent and tempo of collateral development critically determines symptom severity.

The Four Major Collateral Systems:

First, the azygos-hemiazygos system represents the most important and effective collateral pathway. The azygos vein normally drains the posterior chest wall and connects to the SVC just before it enters the right atrium. When SVC obstruction occurs above the azygos junction, blood can flow retrograde from the brachiocephalic veins into intercostal veins, then into the azygos system, which drains directly to the SVC below the obstruction or to the inferior vena cava. This is the most direct pathway and can accommodate the highest flow volume. However, if the obstruction occurs below the azygos insertion, this crucial route is unavailable, leading to more severe symptoms.

Second, the internal mammary veins provide an anterior chest wall collateral route. These vessels connect the subclavian veins superiorly to the inferior epigastric and superficial epigastric veins inferiorly, ultimately draining to the IVC via the external iliac veins. When this pathway develops, dilated veins become visible on the anterior chest and abdominal wall, with flow direction from superior to inferior, which can be confirmed by manual compression.

Third, the lateral thoracic veins create a lateral chest wall pathway, connecting the axillary veins to the superficial circumflex iliac veins and femoral veins. Collaterals via this route also produce visible chest wall veins, predominantly in the lateral chest, with caudal flow direction.

Fourth, the vertebral venous plexus and paravertebral veins provide a deep posterior pathway. This extensive valveless plexus communicates with epidural veins, deep cervical veins, and lumbar veins, eventually draining to the IVC. While invisible on surface examination, this system can be identified on cross-sectional imaging as dilated paraspinal veins.

Clinical Impact of Collateral Development:

The tempo of SVC obstruction determines collateral adequacy and symptom severity. In acute obstruction occurring over hours to days—typical of catheter-related or lead-related thrombosis—collaterals have insufficient time to develop. Central venous pressure rises acutely to 30-40 mmHg, causing severe facial and upper body oedema, profound dyspnoea, and risk of cerebral oedema or laryngeal oedema with airway compromise. These patients require urgent intervention with anticoagulation and potentially stenting.

In subacute obstruction over 2-4 weeks—seen with aggressive malignancies like small cell lung cancer or lymphoma—collaterals partially develop during the obstruction progression. Patients have moderate symptoms with visible collateral veins on examination, but generally avoid life-threatening complications as some venous drainage is re-established.

In chronic obstruction over months—typical of slowly growing tumours, fibrosing mediastinitis, or post-thrombotic scarring—extensive collateral networks develop sufficiently to maintain near-normal venous drainage despite complete SVC occlusion. These patients may be minimally symptomatic or even asymptomatic, with prominent chest wall collaterals evident on examination. The Pemberton sign may paradoxically be negative in these cases despite complete SVC occlusion, as the well-developed collaterals prevent acute pressure rises.

On examination, identifying collateral vein patterns helps determine obstruction level. Flow from superior to inferior indicates SVC obstruction with collaterals draining caudally to the IVC. Unilateral upper extremity veins suggest isolated brachiocephalic vein obstruction with contralateral drainage preserved. The extent of visible collaterals correlates with chronicity—more prominent vessels indicate longer-standing obstruction with established alternative drainage.

Understanding collateral physiology also guides treatment decisions. Patients with acute onset and inadequate collaterals benefit most from urgent stenting to rapidly decompress the venous system. Those with chronic obstruction and extensive collaterals can be managed more conservatively with definitive oncological treatment, as their collaterals maintain adequate drainage during the weeks required for chemotherapy or radiation to reduce tumour burden."

---

Clinical Scenarios for Exam Practice

Scenario 1: Malignant SVCS - Diagnostic Approach

Case Presentation: A 58-year-old male smoker (40 pack-year history) presents to the Emergency Department with a 3-week history of progressive facial swelling, particularly noticeable in the mornings, and increasing dyspnoea on exertion. He reports a 5 kg weight loss over 2 months. On examination, there is facial plethora, non-pulsatile bilateral jugular venous distension, and dilated veins visible across the anterior chest wall with superior-to-inferior flow. Pemberton sign is positive. Observations: HR 92 bpm, BP 138/84 mmHg, RR 22/min, SpO₂ 94% on room air, temperature 37.1°C.

Key Questions to Address:

1. What is your immediate assessment and initial management?
2. What investigations would you arrange urgently?
3. What biopsy technique would you recommend based on typical imaging findings?
4. How would you counsel the patient regarding prognosis?

Suggested Approach:

Immediate Assessment: This presentation is highly suggestive of malignant SVCS given the patient's significant smoking history, constitutional symptoms (weight loss), and subacute symptom onset. The positive Pemberton sign confirms significant venous obstruction. Critically, there are no red flag features indicating life-threatening SVCS—specifically no stridor, altered consciousness, or severe respiratory distress. The SpO₂ of 94% represents mild hypoxia that can be managed supportively.

Initial Management:

• Position patient upright at 30-45 degrees to reduce facial venous pressure
• Administer supplemental oxygen via nasal cannula 2-4 L/min to target SpO₂ > 94%
• Establish IV access via lower extremity (femoral or saphenous vein) to avoid exacerbating upper body venous congestion
• Avoid upper limb venepuncture and blood pressure measurements
• Hold corticosteroids until after tissue sampling (may obscure lymphoma diagnosis)

Urgent Investigations:

• Contrast-enhanced CT chest (venous phase protocol): First-line to confirm SVCS, identify level and cause of obstruction, assess for lung mass, mediastinal lymphadenopathy, and pleural/pericardial involvement. This will guide biopsy technique selection.
• Routine bloods: FBC (anaemia, thrombocytosis), U&Es (renal function before contrast), LFTs (hepatic metastases), LDH (elevated in SCLC and lymphoma), coagulation screen (baseline before biopsy)
• Arterial blood gas: If clinical concern about ventilatory compromise or acid-base disturbance

Expected CT Findings and Biopsy Selection:

Scenario A: Right hilar mass with mediastinal (paratracheal, subcarinal) lymphadenopathy

• Most likely: Lung cancer with nodal involvement
• Recommended biopsy: EBUS-TBNA for mediastinal lymph node sampling
• Rationale: High diagnostic yield (85-95%), minimally invasive, provides staging information, safe in SVCS
• Alternative: If EBUS unavailable or non-diagnostic, CT-guided biopsy of lung mass

Scenario B: Central mediastinal mass without clear lung primary

• Differential: Lymphoma, thymoma, germ cell tumour
• Recommended biopsy: Anterior mediastinoscopy (Chamberlain procedure) or CT-guided core biopsy
• Rationale: Requires adequate tissue for immunohistochemistry (lymphoma subtyping) or germ cell markers; FNA often insufficient
• Send: Tissue for histology, immunohistochemistry, flow cytometry (if lymphoma suspected), tumour markers β-hCG and AFP (if germ cell tumour suspected)

Scenario C: Moderate-to-large pleural effusion present

• Recommended biopsy: Ultrasound-guided thoracentesis as first-line
• Rationale: Easiest, safest, therapeutic (relieves dyspnoea); malignant effusion cytology diagnostic in 60-70%
• Send: Pleural fluid for cytology, biochemistry (protein, LDH), cell count, microbiology if infection suspected
• If cytology negative: Proceed to image-guided pleural biopsy (80-90% yield) or EBUS-TBNA

Definitive Treatment Based on Histology:

Small cell lung cancer (most likely given presentation):

• Staging: Limited-stage vs extensive-stage
• Treatment: Platinum-based combination chemotherapy (cisplatin/carboplatin + etoposide)
• SVCS response: 77% symptom improvement within 2-4 weeks
• Consider concurrent thoracic radiation for limited-stage disease
• Reserve radiotherapy for chemotherapy-refractory SVCS

Non-small cell lung cancer:

• Molecular testing: EGFR mutation, ALK rearrangement, PD-L1 expression
• Treatment: Stage-dependent (surgery if resectable, chemoradiation if locally advanced, systemic therapy if metastatic)
• Consider stenting if severe symptoms or delayed chemotherapy response

Lymphoma:

• Subtype determination via immunohistochemistry
• Treatment: Combination chemotherapy (R-CHOP for DLBCL)
• SVCS response: 80-95% within 1-2 weeks (highly chemosensitive)
• Corticosteroids as part of chemotherapy regimen

Patient Counselling on Prognosis:

"I need to explain that based on your symptoms, examination findings, and smoking history, the most likely cause of your SVC obstruction is lung cancer, though we need tissue diagnosis to confirm this and determine the specific type, as treatment differs significantly.

If this is small cell lung cancer, which is the most common cause of these symptoms in smokers, the cancer is usually advanced but very responsive to chemotherapy. The median survival is approximately 6-12 months depending on extent, though some patients survive longer. The good news is that chemotherapy is highly effective at relieving your current symptoms—about 77% of patients see significant improvement in facial swelling and breathing within 2-4 weeks of starting treatment.

If this is non-small cell lung cancer, prognosis and treatment depend on the stage and whether there are treatable gene mutations. We would need further testing to determine this.

Importantly, the presence of SVC syndrome itself does not necessarily indicate untreatable disease. Once we have the biopsy results, we can provide much more specific information about treatment options and likely outcomes for your particular situation."

---

Scenario 2: Benign Thrombotic SVCS - Management Decisions

Case Presentation: A 45-year-old woman with metastatic breast cancer on active chemotherapy via a right-sided Port-a-Cath (in situ for 8 months) presents with a 5-day history of right arm swelling, facial swelling, and dyspnoea. She is due for chemotherapy today. On examination, her right arm is swollen and erythematous with dilated superficial veins. There is bilateral facial oedema and dilated neck veins. No fever. Observations: HR 98 bpm, BP 128/78 mmHg, RR 24/min, SpO₂ 91% on room air.

CT chest with contrast confirms complete thrombotic occlusion of the right brachiocephalic vein and SVC with the Port-a-Cath tip surrounded by thrombus. No progression of metastatic disease. Bloods: Platelets 180 × 10⁹/L, INR 1.1, APTT 32 seconds (normal), creatinine 68 μmol/L.

Key Management Decisions:

1. Immediate Anticoagulation:

   • Initiate low molecular weight heparin immediately: Enoxaparin 1 mg/kg (e.g., 70 kg patient = 70 mg = 0.7 mL of 100 mg/mL solution) subcutaneously twice daily
   • Rationale: Prevent thrombus propagation and reduce risk of pulmonary embolism
   • Contraindications to check: Active bleeding, severe thrombocytopenia (less than 50 × 10⁹/L), recent CNS haemorrhage, recent surgery (less than 7 days)
   • Duration: Minimum 5-7 days overlapping with oral anticoagulation

2. Catheter Management Decision:

   • Question: Should the Port-a-Cath be removed or retained?
   • Factors to consider:
     • Necessity: Is IV access still required for ongoing chemotherapy? Yes, chemotherapy due today and likely multiple further cycles
     • Alternatives: Could a PICC line or new port be placed? Risk of new catheter thrombosis in already thrombosed venous system
     • Infection: Any signs of line infection (fever, local erythema, bacteraemia)? None in this case
   • Recommendation: Retain Port-a-Cath and continue anticoagulation
   • Evidence: Retained catheters in cancer patients with catheter-related thrombosis on anticoagulation have low recurrence rates (5-10%); catheter remains functional in 70-80%

3. Chemotherapy Decision:

   • Question: Can chemotherapy proceed today given acute thrombosis?
   • Considerations:
     • Bleeding risk: Chemotherapy-induced thrombocytopenia on anticoagulation increases bleeding risk
     • Thrombosis risk: Some chemotherapy agents (cisplatin, L-asparaginase) are prothrombotic
     • Cancer treatment priority: Delaying chemotherapy may compromise cancer control
   • Recommendation: Defer chemotherapy by 1-2 weeks while therapeutic anticoagulation established; reassess platelet count before resuming
   • Discussion with oncology: Consider alternative chemotherapy regimens with lower thrombotic potential if available

4. Thrombolysis Consideration:

   • Question: Should catheter-directed thrombolysis be considered?
   • Indications for thrombolysis in catheter-related SVCS:
     • Acute thrombosis less than 14 days (this case: 5 days - meets criterion)
     • Severe symptoms or limb-threatening ischaemia (present - severe arm swelling, dyspnoea with hypoxia)
     • Failed anticoagulation (not yet tried)
   • Contraindications:
     • Active cancer (relative contraindication - bleeding risk)
     • Recent surgery (less than 10 days)
     • Brain metastases (increased intracranial haemorrhage risk)
     • Thrombocytopenia
   • Recommendation: Trial of anticoagulation first; reserve thrombolysis for anticoagulation failure or deterioration
   • If thrombolysis pursued: Catheter-directed tPA 0.5-1 mg/hour for 12-24 hours with close monitoring; success rate 60-85%

5. Endovascular Stenting Decision:

   • Question: Should SVC stenting be considered now or deferred?
   • Indications for stenting in benign SVCS:
     • Severe symptoms despite anticoagulation
     • Recurrent thrombosis despite therapeutic anticoagulation
     • Absolute contraindication to anticoagulation
     • Chronic complete occlusion with inadequate collaterals
   • Recommendation: Defer stenting initially; trial anticoagulation first
   • Rationale: 70-80% of patients respond to anticoagulation alone within 7-14 days; stenting is reserved for non-responders
   • If symptoms fail to improve after 2 weeks anticoagulation: Consider stenting as second-line

6. Long-Term Anticoagulation:

   • Transition: After 5-7 days LMWH, transition to direct oral anticoagulant
   • Choice: Rivaroxaban 15 mg twice daily for 21 days, then 20 mg once daily OR Apixaban 10 mg twice daily for 7 days, then 5 mg twice daily
   • Alternative: Continue LMWH if active cancer and high bleeding risk (can adjust dose more rapidly than DOACs)
   • Duration:
     • Minimum 3 months if catheter removed
     • 6-12 months if catheter retained and functional
     • Indefinite if recurrent thrombosis, thrombophilia, or permanent device
   • Monitoring: Review at 1 week, 1 month, 3 months, 6 months; check renal function before and during DOAC therapy

7. Symptom Management:

   • Supportive measures:
     • Head elevation 30-45 degrees
     • Supplemental oxygen to maintain SpO₂ > 94%
     • Compression garment for right arm (once anticoagulation established and no contraindications)
     • Avoid right arm venepuncture or BP measurements
     • Limb elevation when resting
   • Diuretics: Consider furosemide 40 mg oral once daily for severe oedema (caution: may reduce cardiac preload)
   • Analgesia: Paracetamol 1 g four times daily for discomfort; avoid NSAIDs (bleeding risk on anticoagulation)

Expected Clinical Course:

• Days 1-3: Symptoms plateau; thrombus stabilisation with anticoagulation
• Days 4-7: Gradual symptom improvement as collaterals develop and oedema reduces
• Weeks 2-4: Significant improvement in 70-80%; right arm swelling resolves; facial oedema improves; dyspnoea resolves
• Month 3: Reassess with venous duplex ultrasound or CT venography; determine ongoing anticoagulation need

Follow-Up Plan:

• Week 1: Clinical review, check platelet count (anticipate nadir from chemotherapy), assess bleeding complications
• Week 2: Assess symptom response to anticoagulation; if poor response, consider imaging and stenting
• Month 1: Symptom review, check renal function, assess compliance with anticoagulation
• Month 3: Imaging (duplex ultrasound or CT venography) to assess vessel recanalisation; decide anticoagulation duration
• Month 6: If still on anticoagulation, review bleeding/thrombosis balance; consider indefinite therapy given malignancy and retained port

Red Flags Prompting Urgent Reassessment:

• Worsening dyspnoea or stridor (progression to critical SVCS)
• Chest pain or haemodynamic instability (consider pulmonary embolism)
• Significant bleeding (epistaxis, haematuria, GI bleeding)
• Severe headache or altered consciousness (cerebral venous thrombosis or intracranial haemorrhage)

---

Scenario 3: SVCS with Difficult Airway Management

Case Presentation: A 62-year-old man with known SCLC diagnosed 2 weeks ago presents to the Emergency Department with acute worsening dyspnoea over 6 hours, now with inspiratory stridor audible at rest. He has significant facial and tongue swelling. Chemotherapy was due to start today but not yet administered. On examination, he is sitting upright, using accessory muscles, with audible stridor. Facial and tongue oedema present. SpO₂ 88% on 15 L oxygen via non-rebreather mask. HR 118 bpm, BP 156/92 mmHg, RR 32/min. GCS 15.

CT chest from 1 week ago showed extensive mediastinal lymphadenopathy encasing the SVC with complete obstruction, bulky right hilar mass, and tracheal compression.

Emergency Management:

Immediate Actions (Simultaneous):

1. Call for help: Anaesthetics, ICU, interventional radiology
2. High-flow oxygen: Continue 15 L via non-rebreather; consider non-invasive ventilation (CPAP 5-10 cmH₂O may temporise but risk of worsening venous return)
3. Position: Sit upright 90 degrees; lying flat will worsen symptoms
4. IV access: Femoral vein (avoid upper extremity)
5. Immediate corticosteroids: Dexamethasone 16 mg IV bolus (reduces laryngeal and airway oedema within 6-12 hours)
6. Nebulised adrenaline: 5 mg (5 mL of 1:1,000) nebulised; may provide temporary airway oedema reduction
7. Avoid sedation: Will obtund respiratory drive and worsen hypoxia

Airway Assessment:

• Life-threatening features present: Stridor, hypoxia despite high-flow oxygen, tachypnoea, use of accessory muscles
• Intubation risk: Extremely high-risk due to:
  • Venous engorgement in airway making direct laryngoscopy difficult and increasing bleeding risk
  • Loss of respiratory effort after induction may precipitate cardiovascular collapse (loss of negative intrathoracic pressure worsens venous return)
  • Positive pressure ventilation reduces venous return, potentially causing cardiovascular collapse
  • Tracheal compression from mediastinal mass may prevent endotracheal tube passage

Anaesthetic Consultation - Management Options:

Option 1: Awake Fibreoptic Intubation

• Maintains spontaneous ventilation throughout
• Local anaesthesia to airway (topical lidocaine)
• Minimal sedation (small doses of midazolam/fentanyl; avoid propofol/thiopentone)
• Fibreoptic scope passed through vocal cords under direct vision
• Endotracheal tube railroaded over scope
• Risk: May not be possible if airway anatomy distorted; coughing can worsen venous pressure

Option 2: Urgent SVC Stenting

• Performed by interventional radiology under local anaesthesia
• Femoral vein access; venography to delineate SVC anatomy
• Self-expanding stent deployed across SVC obstruction
• Immediate SVC decompression
• Symptom improvement within 2-6 hours in 85-95%
• Advantage: Treats underlying cause without requiring intubation
• Recommended as first-line in this scenario: Decompresses SVC, improves venous drainage, reduces airway oedema, avoids high-risk intubation

Option 3: Tracheostomy

• Performed under local anaesthesia in awake patient
• Bypasses supraglottic and glottic oedema
• Secures airway definitively
• Risk: Bleeding from venous engorgement; technical difficulty; does not address tracheal compression below stoma level

Recommended Approach for This Case:

Step 1 (Immediate - 0-30 minutes):

• Dexamethasone 16 mg IV stat
• Nebulised adrenaline 5 mg
• Oxygen therapy as tolerated
• Urgent anaesthetic assessment
• Contact interventional radiology for urgent SVC stenting availability

Step 2 (30-60 minutes):

• If interventional radiology available within 1 hour: Proceed directly to urgent SVC stenting under local anaesthesia
  • Continuous monitoring by anaesthetist during procedure
  • Airway equipment at bedside (difficult intubation trolley, surgical airway kit)
  • "If airway deteriorates during procedure: Emergency fibreoptic intubation or surgical airway"
• If interventional radiology not available urgently: Consider transfer to tertiary centre with interventional capability vs proceeding to awake fibreoptic intubation by experienced anaesthetist

Step 3 (Post-Stenting):

• Continue dexamethasone 8 mg IV every 6 hours for 48 hours
• Monitor in ICU/HDU for 24 hours
• Expect gradual symptom improvement over 6-24 hours
• Once stabilised (usually 24-48 hours): Initiate chemotherapy
• SCLC chemotherapy will provide definitive treatment; stent maintains SVC patency during treatment

Crucial Points:

• Do NOT induce general anaesthesia for intubation without senior anaesthetic input: High risk of cardiovascular collapse
• Do NOT lay patient flat: Worsens venous return and airway oedema; may precipitate complete obstruction
• Stenting is treatment of choice: Provides definitive SVC decompression without airway manipulation
• Dexamethasone buys time: Reduces oedema over 6-12 hours; allows temporising while arranging definitive treatment

If Complete Airway Obstruction Occurs:

• Cannot intubate, cannot oxygenate scenario
• Emergency front-of-neck access (cricothyroidotomy or emergency tracheostomy)
• Surgical airway kit at bedside
• ENT surgeon involvement if time permits

Long-Term Management:

• After stabilisation: Platinum-based chemotherapy for SCLC (cisplatin + etoposide)
• Expect SVCS symptom resolution within 2-4 weeks of chemotherapy
• Stent remains in situ; provides scaffolding during tumour response

Outcome Data:

• Urgent SVC stenting in life-threatening SVCS: 95% technical success
• Symptom improvement within 24 hours: 85-90%
• Avoidance of intubation: 80-90% (stenting prevents airway deterioration)
• Mortality from emergency airway intervention in SVCS: 5-10% (highlighting importance of avoiding intubation if possible)

---

References

1. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore). 2006;85(1):37-42. doi:10.1097/01.md.0000198474.99876.f0
2. Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007;356(18):1862-1869. doi:10.1056/NEJMcp067190
3. Wan JF, Bezjak A. Superior vena cava syndrome. Emerg Med Clin North Am. 2009;27(2):243-255. doi:10.1016/j.emc.2009.01.003
4. Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol. 1997;8(5):781-788. doi:10.1016/S1051-0443(97)70660-2
5. Wijesuriya N, Sinabulya H, Johann-Meyer H, et al. Joint Pacing and Vascular Intervention for the Management of Cardiac Device Associated Central Venous Obstruction. Pacing Clin Electrophysiol. 2025;48(8):1018-1028. doi:10.1111/pace.70019
6. Vardar U, Burright I, Lee B, et al. Management of Lead-Related Superior Vena Cava Syndrome: Clinical and Procedural Outcomes. JACC Clin Electrophysiol. 2026;12(3):452-461. doi:10.1016/j.jacep.2025.12.014
7. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol). 2002;14(5):338-351. doi:10.1053/clon.2002.0108
8. Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys. 1987;13(4):531-539. doi:10.1016/0360-3016(87)90068-X
9. Klein-Weigel PF, Elitok S, Ruttloff A. Superior vena cava syndrome. Vasa. 2020;49(6):453-464. doi:10.1024/0301-1526/a000908
10. Abuelatta R, Sakrana AA, Al-Zubaidi SA. Diathermy-assisted recanalization of chronic superior vena cava obstruction, case report. Radiol Case Rep. 2020;15(8):1274-1277. doi:10.1016/j.radcr.2020.05.002
11. Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. Springerplus. 2016;5:229. doi:10.1186/s40064-016-1900-7
12. Parish JM, Marschke RF Jr, Dines DE, Lee RE. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc. 1981;56(7):407-413.
13. Oh A, Durojaye O, Rahimi M, et al. Large-bore catheter selection in endovascular management of superior vena cava syndrome. J Vasc Surg Cases Innov Tech. 2025;11(1):101977. doi:10.1016/j.jvscit.2025.101977
14. Vardar U, Burright I, Lee B, et al. Management of Lead-Related Superior Vena Cava Syndrome: Clinical and Procedural Outcomes. JACC Clin Electrophysiol. 2026;12(3):452-461. doi:10.1016/j.jacep.2025.12.014
15. Aung EY, Khan M, Williams N, et al. Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2022;45(10):1428-1444. doi:10.1007/s00270-022-03178-z
16. Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg. 1986;41(2):158-163. doi:10.1016/s0003-4975(10)62651-5
17. Joshi A, Law J, Shah N. Superior and inferior vena cava syndrome caused by a rare lung cancer: A case report. Clin Case Rep. 2024;12(9):e9391. doi:10.1002/ccr3.9391
18. Chopra V, Anand S, Hickner A, et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet. 2013;382(9889):311-325. doi:10.1016/S0140-6736(13)60592-9
19. Mathisen DJ, Grillo HC. Clinical manifestation of mediastinal fibrosis and histoplasmosis. Ann Thorac Surg. 1992;54(6):1053-1057. doi:10.1016/0003-4975(92)90068-l
20. Kee ST, Kinoshita L, Razavi MK, et al. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology. 1998;206(1):187-193. doi:10.1148/radiology.206.1.9423671
21. Escalante CP. Causes and management of superior vena cava syndrome. Oncology (Williston Park). 1993;7(6):61-68.
22. Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. Am J Surg. 1990;160(2):207-211. doi:10.1016/s0002-9610(06)80028-7
23. Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome—a proposed classification system and algorithm for management. J Thorac Oncol. 2008;3(8):811-814. doi:10.1097/JTO.0b013e3181804791
24. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome. The myth—the facts. Am Rev Respir Dis. 1990;141(5 Pt 1):1114-1118. doi:10.1164/ajrccm/141.5_Pt_1.1114
25. Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena caval obstruction. Is it a medical emergency? Am J Med. 1981;70(6):1169-1174. doi:10.1016/0002-9343(81)90319-4
26. Akoglu H, Yilmaz R, Kirkpantur A, et al. Combineduse of Pemberton's sign and echocardiography in the evaluation of thoracic inlet obstruction. Med Princ Pract. 2006;15(4):262-265. doi:10.1159/000092988
27. Kishi K, Sonomura T, Mitsuzane K, et al. Self-expandable metallic stent therapy for superior vena cava syndrome: clinical observations. Radiology. 1993;189(2):531-535. doi:10.1148/radiology.189.2.8210386
28. Spodick DH. Acute cardiac tamponade. N Engl J Med. 2003;349(7):684-690. doi:10.1056/NEJMra022643
29. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102 Suppl 1:S2-S9. doi:10.1038/sj.bjc.6605599
30. Leigh-Smith S, Harris T. Tension pneumothorax—time for a re-think? Emerg Med J. 2005;22(1):8-16. doi:10.1136/emj.2003.010421
31. Bhave AD, Franssen N, et al. ACR Appropriateness Criteria® Thoracic Venous Occlusions—Suspected Superior Vena Cava Syndrome. J Am Coll Radiol. 2026;23(2):S15-S26. doi:10.1016/j.jacr.2025.10.029
32. Kvale PA, Selecky PA, Prakash UB; American College of Chest Physicians. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):368S-403S. doi:10.1378/chest.07-1390
33. Minna JD, Pass H, Glatstein E, Ihde DC. Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: Lippincott; 1993:673-723.
34. Kim HJ, Kim HS, Chung SH. CT diagnosis of superior vena cava syndrome: importance of collateral vessels. AJR Am J Roentgenol. 1993;161(3):539-542. doi:10.2214/ajr.161.3.8352099
35. Stanford W, Jolles H, Ell S, Chiu LC. Superior vena cava obstruction: a venographic classification. AJR Am J Roentgenol. 1987;148(2):259-262. doi:10.2214/ajr.148.2.259
36. Haponik EF, Fein A, Chin R. Managing life-threatening hemoptysis: has anything really changed? Chest. 2000;118(5):1431-1435. doi:10.1378/chest.118.5.1431
37. Yasufuku K, Pierre A, Darling G, et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg. 2011;142(6):1393-1400. doi:10.1016/j.jtcvs.2011.08.037
38. Black KR, Eloubeidi MA. Superior vena cava syndrome: diagnosis of etiology with EUS-guided FNA. Gastrointest Endosc. 2008;67(2):372-374. doi:10.1016/j.gie.2007.08.015
39. Gupta S, Wallace MJ, Cardella JF, et al. Quality improvement guidelines for percutaneous needle biopsy. J Vasc Interv Radiol. 2010;21(7):969-975. doi:10.1016/j.jvir.2010.01.011
40. Yasufuku K, Nakajima T, Fujiwara T, et al. Utility of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of mediastinal masses of unknown etiology. Ann Thorac Surg. 2011;91(3):831-836. doi:10.1016/j.athoracsur.2010.11.032
41. Screaton NJ, Benamore RE, Gleeson FV. The use of spiral CT in the diagnosis and management of lung cancer. Clin Radiol. 2003;58(6):412-425. doi:10.1016/s0009-9260(03)00083-0
42. Porcel JM. Diagnosis and characterization of pleural effusions. Expert Rev Respir Med. 2010;4(5):631-643. doi:10.1586/ers.10.59
43. Wang H, Liu ZY, Liu CY, et al. Catheter-directed thrombectomy combined with angioplasty and stent implantation for superior vena cava syndrome: a case report. Transl Cancer Res. 2026;15(1):246-253. doi:10.21037/tcr-2025-aw-2492
44. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter-related sepsis. Chest. 1998;114(1):207-213. doi:10.1378/chest.114.1.207
45. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026
46. Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg. 1986;41(2):158-163. doi:10.1016/s0003-4975(10)62651-5
47. Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol. 1984;2(8):961-969. doi:10.1200/JCO.1984.2.8.961
48. Wurschmidt F, Bünemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys. 1995;33(1):77-82. doi:10.1016/0360-3016(95)00026-8
49. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood. 2014;123(12):1794-1801. doi:10.1182/blood-2013-12-512681
50. Miyayama S, Yamashiro M, Ikeda R, et al. Endovascular Treatment for Upper Body Central Venous Obstruction. Interv Radiol. 2025;10(2):81-89. doi:10.22575/interventionalradiology.2023-0043
51. Banaszkiewicz M, Kurzyna P, Darocha S, et al. Safety and outcomes of endovascular treatment with stent implantation in patients with malignant superior vena cava syndrome: single-center experience. Pol Arch Intern Med. 2025;135(4):17003. doi:10.20452/pamw.17003
52. Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med. 1993;153(3):384-387.
53. Ruckdeschel JC, Loehrer PJ Sr. Non-small cell lung cancer. In: Abeloff MD, Armitage JO, Niederhuber JE, et al, eds. Abeloff's Clinical Oncology. 4th ed. Philadelphia: Churchill Livingstone Elsevier; 2008:1353-1392.
54. Thacker N, Bakhshi S, Chinnaswamy G, et al. Management of Non-Hodgkin Lymphoma: ICMR Consensus Document. Indian J Pediatr. 2017;84(6):438-446. doi:10.1007/s12098-017-2318-0
55. Albany C, Einhorn LH. Extragonadal germ cell tumors: clinical presentation and management. Curr Opin Oncol. 2013;25(3):261-265. doi:10.1097/CCO.0b013e32835edb06
56. Chan RH, Dar AR, Yu E, et al. Superior vena cava obstruction in small-cell lung cancer. Int J Radiat Oncol Biol Phys. 1997;38(3):513-520. doi:10.1016/s0360-3016(97)00009-6
57. Patel A, Haldar N, Micaily I, et al. Urgent radiotherapy for superior vena cava syndrome in metastatic non-small cell lung cancer: a case report. Tech Innov Patient Support Radiat Oncol. 2026;30:100365. doi:10.1016/j.tipsro.2025.100365
58. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21(19):3665-3675. doi:10.1200/JCO.2003.08.008
59. Kee ST, Kinoshita L, Razavi MK, et al. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology. 1998;206(1):187-193. doi:10.1148/radiology.206.1.9423671
60. Aung EY, Khan M, Williams N, et al. Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2022;45(10):1428-1444. doi:10.1007/s00270-022-03178-z
61. Rizvi AZ, Kalra M, Bjarnason H, et al. Benign superior vena cava syndrome: stenting is now the first line of treatment. J Vasc Surg. 2008;47(2):372-380. doi:10.1016/j.jvs.2007.09.071
62. Haddad MM, Thompson SM, McPhail IR, et al. Is Long-Term Anticoagulation Required after Stent Placement for Benign Superior Vena Cava Syndrome? J Vasc Interv Radiol. 2019;30(2):229-236. doi:10.1016/j.jvir.2018.07.020
63. Loyd JE, Tillman BF, Atkinson JB, Des Prez RM. Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore). 1988;67(5):295-310. doi:10.1097/00005792-198809000-00002
64. Rioja Artal S, González Martínez V, Royo Serrando J, et al. Results of Palliative Stenting in Malignant Superior Vena Cava Syndrome Analyzing Self-Expanding Stainless Steel and Nitinol Venous Bare Metal Stents. J Endovasc Ther. 2024;31(6):1137-1146. doi:10.1177/15266028241242926
65. Nagata T, Makutani S, Uchida H, et al. Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc Intervent Radiol. 2007;30(5):959-967. doi:10.1007/s00270-007-9088-4
66. Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-292. doi:10.1007/s11739-012-0784-y
67. Chopra V, Montoya A, Joshi D, et al. Peripherally inserted central catheter use in skilled nursing facilities: a pilot study. J Am Geriatr Soc. 2015;63(9):1894-1899. doi:10.1111/jgs.13621
68. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 5.2024. Accessed January 10, 2026.
69. British Thoracic Society. BTS Guidelines: The Diagnosis and Treatment of Lung Cancer. Thorax. 2001;56(Suppl 1):i1-i64.
70. Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(7):839-853. doi:10.1016/j.annonc.2021.03.207